oncology
CHICAGO—A 25 per cent risk reduction for esophageal cancer was found to be associated with prophylactic therapy consisting of a proton pump inhibitor (PPI) and aspirin in the phase three randomized ASPECT multicenter study from the United Kingdom reported at …
CHICAGO—Findings from a Phase III trial show that initial single-agent therapy with a new oral drug called afatinib prolongs progression- free survival in patients with advanced lung adenocarcinomas that harbour EGFR mutations, compared with current standard treatment. Afatinib broadly blocks …
CHICAGO—At the Plenary Session of ASCO Maha Hussain MD, FACP of the University of Michigan in Ann Arbor presented results from a long-term, multicenter Phase III international clinical trial comparing two common therapies for men with hormone-sensitive metastatic prostate cancer. …
